Related Experiment Video
Updated: Sep 16, 2025

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
Published on: April 11, 2019
Seizure outcome in adult patients with valproic acid treated epilepsy: gender-related differences
Revital Gandelman-Marton1, Jacques Theitler1
1Neurology Department, Shamir-Assaf Harofeh Medical Center, Zerifin, Israel; Faculty of Medical & Health Sciences, Tel Aviv University, Israel.
Background:
Seizure control following Valproic Acid (VPA) withdrawal and the effects of VPA avoidance were mainly studied in women of childbearing age. Currently, there are limited and conflicting data regarding gender outcomes following VPA withdrawal or switch to another Antiseizure Medication (ASM).
Objective:
To evaluate gender outcomes in a cohort of patients with VPA-treated epilepsy and to assess their relation to VPA treatment patterns.
Methods:
A retrospective review of the computerized database and the medical records of patients who presented to their first visit in our adult epilepsy outpatient clinic during a 10-year period (2012-2021). Of the 142 patients identified, 79 continued their follow-up in the clinic and were included in the study.
Results:
The study group included 50 (63.3 %) men and 29 (36.7 %) women, aged 18-83 years (median - 24 y). VPA was discontinued in 17 (21.5 %) patients, more commonly in women compared to men (41.4 % vs 10 %) (p = 0.004). Seizure outcome at last observation was worse in women (p = 0.023) and did not significantly differ according to VPA treatment patterns during follow-up. The prescribed daily dose/defined daily dose ratios for VPA and concomitant ASMs did not significantly differ between men and women at last observation.
Conclusions:
Women are more likely to have a worse seizure outcome, regardless of VPA treatment pattern. Further studies are needed to assess the best treatment options in women with epilepsy.
More Related Videos
Related Concept Videos
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Glutamate Antagonists

